



## Inter-laboratory evaluation of instrument platforms and experimental workflows for quantitative accuracy and reproducibility assessment



Andrew J. Percy<sup>a</sup>, Jessica Tamura-Wells<sup>a</sup>, Juan Pablo Albar<sup>b,1</sup>, Kerman Aloria<sup>c</sup>, Ardeshir Amirkhani<sup>d</sup>, Gabriel D.T. Araujo<sup>e</sup>, Jesus M. Arizmendi<sup>f</sup>, Francisco J. Blanco<sup>g,h</sup>, Francesc Canals<sup>i</sup>, Jin-Young Cho<sup>j</sup>, Núria Colomé-Calls<sup>i</sup>, Fernando J. Corrales<sup>k</sup>, Gilberto Domont<sup>e</sup>, Guadalupe Espadas<sup>l,m</sup>, Patricia Fernandez-Puente<sup>g</sup>, Concha Gil<sup>n</sup>, Paul A. Haynes<sup>o</sup>, Maria Luisa Hernández<sup>n</sup>, Jin Young Kim<sup>p</sup>, Arthur Kopylov<sup>q</sup>, Miguel Marcilla<sup>b</sup>, Mathew J. McKay<sup>d</sup>, Mehdi Mirzaei<sup>o</sup>, Mark P. Molloy<sup>d</sup>, Leanne B. Ohlund<sup>r</sup>, Young-Ki Paik<sup>j</sup>, Alberto Paradela<sup>b</sup>, Mark Raftery<sup>s</sup>, Eduard Sabidó<sup>l,m</sup>, Lekha Sleno<sup>r</sup>, Daniel Wilffert<sup>t</sup>, Justina C. Wolters<sup>t</sup>, Jong Shin Yoo<sup>p</sup>, Victor Zgodar<sup>q</sup>, Carol E. Parker<sup>a</sup>, Christoph H. Borchers<sup>a,u,\*</sup>

<sup>a</sup> University of Victoria—Genome British Columbia Proteomics Centre, Vancouver Island Technology Park, #3101-4464 Markham St., Victoria, BC V8Z 7X8, Canada

<sup>b</sup> Proteomics Facility, Centro Nacional de Biotecnología (CSIC), UAM Campus Cantoblanco, Darwin, 3, Madrid E-28049, Spain

<sup>c</sup> Proteomics Core Facility-SGIKER, University of the Basque Country (UPV/EHU), Leioa 48940, Spain

<sup>d</sup> Australian Proteome Analysis Facility, Macquarie University, Sydney NSW 2109, Australia

<sup>e</sup> Proteomics Unit of the Department of Biochemistry, Institute of Chemistry, Federal University of Rio de Janeiro, Rio de Janeiro 21941-909, Rio de Janeiro, Brazil

<sup>f</sup> Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), Barrio Sarriena s/n, Leioa 48940, Spain

<sup>g</sup> Grupo de Proteómica-ProteoRed/Plataforma PBR2-ISCIII, Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, A Coruña 15006, Spain

<sup>h</sup> CIBER-BBN/ISCIII, Instituto de Investigación Biomédica de A Coruña INIBIC-Hospital Universitario A Coruña, A Coruña 15006, Spain

<sup>i</sup> Laboratori de Proteòmica, Institut de Recerca Hospital Univ. Vall d'Hebron. Edifici Collserola, Pg. Vall d'Hebron, 119-129, Barcelona 08035, Spain

<sup>j</sup> Yonsei Proteome Research Center and Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, South Korea

<sup>k</sup> Center for Applied Medical Research (CIMA), University of Navarra, ProteoRed-ISCIII, CIBERHED-ISCIII, IDISNA, Pío XII, 55; Ed. CIMA, Pamplona 31008, Spain

<sup>l</sup> Proteomics Unit, Center of Genomics Regulation (CRG), Carrer Dr. Aiguader 88, Barcelona 08003, Spain

<sup>m</sup> Proteomics Unit, Universitat Pompeu Fabra, Carrer Dr. Aiguader 88, Barcelona 08003, Spain

<sup>n</sup> Department of Microbiology II and Proteomics Unit UCM-PCM Complutense University of Madrid, Plaza Ramón y Cajal s/n, Madrid 28040, Spain

<sup>o</sup> Department of Chemistry and Biomolecular Sciences, Macquarie University, North Ryde NSW 2109, Australia

<sup>p</sup> Division of Mass Spectrometric Analysis, Korea Basic Science Institute, Cheongwon, South Korea

<sup>q</sup> Institute of Biomedical Chemistry, Pogodinskaya Street 10, Moscow 119121, Russian Federation

<sup>r</sup> Université du Québec à Montréal, CP 8888 Succ. Centre-Ville Montreal QC H3P 3P8, Canada

<sup>s</sup> Bioanalytical Mass Spectrometry, Wallace Wurth Building, University of New South Wales, Sydney NSW 2052, Australia

<sup>t</sup> Department of Pharmacy, Analytical Biochemistry, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands

<sup>u</sup> Department of Biochemistry and Microbiology, University of Victoria, Petch Building Room 207, 3800 Finnerty Rd., Victoria, BC V8P 5C2, Canada

### ARTICLE INFO

#### Article history:

Received 27 March 2015

Received in revised form 1 June 2015

Accepted 10 June 2015

Available online 11 June 2015

### ABSTRACT

The reproducibility of plasma protein quantitation between laboratories and between instrument types was examined in a large-scale international study involving 16 laboratories and 19 LC–MS/MS platforms, using two kits designed to evaluate instrument performance and one kit designed to evaluate the entire bottom-up workflow. There was little effect of instrument type on the quality of the results, demonstrating the robustness of LC/MRM–MS with isotopically labeled standards. Technician skill was a factor, as errors in sample preparation and sub-optimal LC–MS performance were evident. This highlights

\* Corresponding author at: University of Victoria—Genome British Columbia Proteomics Centre, Vancouver Island Technology Park, #3101-4464 Markham St., Victoria V8Z 7X8, Canada. Fax: +1 250 483 3238.

E-mail address: [christoph@proteincentre.com](mailto:christoph@proteincentre.com) (C.H. Borchers).

<sup>1</sup> Deceased.

**Keywords:**

Accuracy  
Human plasma  
Quality control  
Quantitative proteomics  
Reproducibility  
Workflow validation

the importance of proper training and routine quality control before quantitation is done on patient samples.

© 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).


## 1. Introduction

Reproducible and accurate quantitation is a requirement for clinical and translational applications in targeted proteomics. The “gold standard” method in MS-based proteomics relies on multiple reaction monitoring (MRM) with stable isotope-labeled standards (SIS) incorporated within a bottom-up workflow [1]. Although MRM with labeled standards has been used for decades in small-molecule analysis (e.g., hormones, drugs) [2,3], the use of this technique in proteomics introduces additional analytical variables related to sample preparation (e.g., digestion) that increases the complexity of the sample analysis, thereby increasing the potential for interferences with the MRM transitions. To address this, standardization of proteomics methods has been encouraged by the Human Proteomics Proteome Organization’s Plasma Proteome Project [4–10] and supported further by the US National Cancer Institute through the Clinical Proteomic Tumor Analysis Consortium [11,12]. This is necessary to enhance the global reproducibility of high quality data using different MS technologies.

As part of this standardization effort, we previously developed three standardization kits for instrument QC on a daily (Kit A) or monthly (Kits B and C) basis for LC-MS/MS platform (Kits A and B)

and complete workflow (Kit C) assessment [13,14]. These kits contain a set of materials and analysis tools that enable value tracking and accuracy estimation by comparison with a set of reference values/ranges. Lyophilized pre-digested plasma standards that were spiked with a SIS peptide mixture (43 peptides from 43 human plasma proteins) are provided in Kits A and B, while raw starting materials (namely undepleted plasma, trypsin, and the SIS mix) are provided in Kit C for sample preparation and subsequent processing/analysis. In all cases, samples are processed by LC-MS/MS in a targeted or semi-targeted manner (i.e., by using MRM on a triple quadrupole mass spectrometer or by using parallel reaction monitoring (PRM) on a hybrid quadrupole-Orbitrap mass spectrometer, respectively). These operative modes differ in that precursor-product ion pairs (i.e., transitions) are sequentially monitored in MRM, whereas in PRM, full product ion spectra are collected from the collisional fragmentation of all target precursors in a given  $m/z$  window (see Fig. 1a and b in [15] for comparative schematics).

In this paper, we report the use of these three kits to evaluate the accuracy and reproducibility of a quantitative proteomics analysis of 43 high-to-moderate abundance plasma proteins in a bottom-up workflow, and to determine the source of errors if sub-



**Fig. 1.** Experimental workflows and starting points for the 3 QC kits. Kits A and B required simple rehydration of the lyophilized peptide mixture(s) prior to sample processing by LC/MRM-MS or LC/PRM-MS, whereas Kit C required the user to execute the entire workflow from 3 supplied starting materials (namely plasma, trypsin, and the SIS mix). Kit dispersal and data/quantitative analysis were performed at the UVic-Genome BC Proteomics Centre. Quantitation was facilitated by Qualis-SIS which generated standard curves (relative response vs. SIS concentration) from the SIS (red trace) and NAT (blue trace) response data of each peptide’s quantifier transition. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Download English Version:

<https://daneshyari.com/en/article/1184434>

Download Persian Version:

<https://daneshyari.com/article/1184434>

[Daneshyari.com](https://daneshyari.com)